PB0628 - The characterization of clot-fibrinolysis waveform analysis and the investigation of usefulness in critical care patients with enhanced or suppressed fibrinolysis

Monday, July 11, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

Osamu Kumano, PhD

Project Coordination Manager
HYPHEN BioMed
Neuville Sur Oise, Centre, France

Co-Author(s)

TT

Takumi Tsuchida

Department of Emergency Medicine
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
MH

Mineji Hayakawa

Department of Emergency Medicine
Hokkaido University Hospital
Sapporo, Hokkaido, Japan

Background: A well-controlled balance between pro-coagulant, anti-coagulant and fibrinolytic mechanisms is critical for maintain normal haemostasis in circulating blood. Especially, the fibrinolysis situation is changing in critical care patients, remarkably. It is useful to investigate the fibrinolysis situation with coagulation simultaneously in these patients.

Aims: Recently, clot-fibrinolysis waveform analysis (CFWA) which is the coagulation and fibrinolysis global assay based on activated partial thromboplastin time with tissue-type plasminogen activator was developed. In this study, the characteristics of CFWA was investigated by samples from enhanced or suppressed fibrinolysis patients in critical care.

Methods: The fibrinolysis times of CFWA were detected as CFWA-Lys in the total 299 samples. These samples were divided into three groups based on the reference interval (RI) of CFWA: Group 1, less than RI; Group 2, within RI; Group 3, more than RI. The coagulation and fibrinolysis markers including fibrin/fibrinogen degradation products (FDP), D-dimer, plasmin-α2 plasmin inhibitor complex (PIC), fibrin monomer complex (FMC), Plasmin-α2 Plasmin Inhibitor (α2PI), Plasminogen (Plg) and fibrinogen (Fbg) were investigated and compared among three groups. The informed consent was obtained from patients.

Results: The significant differences were recognized between group 1 and 3 in FDP, FMC, α2PI, Plg and Fbg. The values of FDP and FMC in group 1 were higher than those of group 3, the other parameters showed lower values in group 1 than group 3. Especially, the values of α2PI and Fbg became higher from the order of group 1, 2 and 3, significantly.

Conclusion(s): CFWA-Lys was largely related to the values of α2PI and Fbg, and it was considered that CFWA-Lys was prolonged in the samples with high concentration of plasmin inhibitor and large firmness clot derived from high concentration Fbg. CFWA-Lys may be useful to investigate the fibrinolysis situation as the global assay.